Podcasts about regulatory

It hasn't been in many headlines (thanks, AI), but pharmaceutical companies are on a merger & acquisition spree that could break records. With more than $126 billion in deals so far this year, companies are looking for novel drug canddiates and clinical stage companies to bolster their own development pipeline. We'll take a dive into what's driving this M&A frenzy and what companies look interesting in the pharmaceutical space today.Tyler Crowe, Matt Frankel, and Lou Whiteman discuss:- Big Pharma using big wallets for M&A- Who's at risk of running off a patent cliff- Regulatory changes adding fuel to the fire- Companies doing great for patients (and investors)- Mailbag: Is Pfizer ok? Companies discussed: LLY, MRK, UTHR, ASND, PFE, ABBV, GSK, NVO, RHHBYHost: Tyler CroweGuests: Matt Frankel, Lou WhitemanEngineer: Bart Shannon Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

After a two-year hiatus, the PEPPER (Program for Evaluating Payment Patterns Electronic Report) is back. It's now available to all acute care hospitals and critical access hospitals. During the next live edition of Talk Ten Tuesday, Dr. Ronald Hirsch will share some insights that listeners can get from their PEPPER to improve their hospital's compliance, quality, and revenue.  To learn more, register now to secure your seat at the table during the next live edition of Talk Ten Tuesdays, coming up at 10 a.m. EST on Tuesday, June 23.Other well-known subject-matter experts will also join the broadcast with more news to report, including the following: •Tech Report: Senior healthcare analyst Frank Cohen concludes the third installment in his three-part series on AI and coding.•POV: Penny Jefferson, cohost of Talk Ten Tuesdays, will share her point of view (POV) during the broadcast.•The Coding Report: Rose Dunn, who will substitute for Christine Geiger, will report on the latest coding news.•CDI Report: Cheryl Ericson will provide an update on clinical documentation integrity (CDI).•SDoH Report: Tiffany Ferguson, the CEO for Phoenix Medical Management, will report on news that's happening at the intersection of patient care and medical record coding

Episode 4 of Rethinking EHS, Season 3 focuses on the fast-growing data center sector and the need to balance speed, innovation, and sustainability. The episode explores how global demand for digital infrastructure is accelerating rapidly, driven by cloud adoption, AI, and increasing digital consumption, while physical constraints such as power, space, and water are shaping where and how data centres are developed. Emerging hubs like Milan are gaining prominence as traditional markets reach capacity, supported by evolving regulatory frameworks that are beginning to recognise data centers as strategic infrastructure. Looking ahead, the industry's future will depend on improving safety maturity, strengthening collaboration across the supply chain, and ensuring data centers are developed as responsible “neighbours” that minimise environmental impact. Ultimately, global collaboration, combined with local knowledge, will be key to scaling the sector sustainably and building a more resilient digital infrastructure. --- Guest quotes: Julie Kreger-King: “There's a real tension between the need for speed and the need to put strong systems and processes in place.” Alessandro Intile: “We are not building warehouses or chemical plants—we are exactly in the middle, with risks that must be carefully managed.” --- Timestamps: 00:00:00 – Introduction & data centre growth overview 00:01:10 – What's driving global demand (cloud, AI, digitalisation) 00:02:31 – Emerging hubs and regulatory developments in Europe 00:04:25 – Regulatory differences between regions 00:05:51 – Why data centres are a critical EHS focus area 00:08:08 – Safety maturity across the sector 00:10:10 – Balancing speed vs systems and processes 00:12:21 – Technology evolution and new risk factors 00:14:03 – Supply chain and quality challenges 00:16:06 – Brownfield development and environmental risks 00:20:13 – Overlooked risks: noise, fuel storage, permitting 00:22:35 – Achieving global consistency vs local requirements 00:28:24 – Advice for EHS professionals entering the sector 00:32:31 – Future ESG priorities and industry maturity 00:36:03 – The role of global collaboration 00:38:01 – Closing reflections --- Sponsor Copy Rethinking EHS is brought to you by the Inogen Alliance. Inogen Alliance is a global network of 70+ companies providing environment, health, safety, and sustainability services, working together to provide one point of contact to guide multinational organizations to meet their global commitments locally.  Visit inogenalliance.com to learn more. --- Links https://Inogenalliance.com/resources https://Inogenalliance.com/podcast Julie on LinkedIn: https://www.linkedin.com/in/julie-kreger-king/  Charlotte on LinkedIn: https://www.linkedin.com/in/charlotte-buffoni-a42b9629/ Alessandro on LinkedIn: https://www.linkedin.com/in/alessandro-intile-5730a2124/?skipRedirect=true  Produced by https://madcontent.co.nz/  

Open seasons are a key part of marketing capacity for gas pipeline and storage projects, but they can also raise several regulatory questions. And the answers depend on what kind of open season it is. Today, we take a deep dive into the ins and outs of a gas project open season.

In this episode of Medsider Radio, we sat down with Eric Kau, co-founder and CEO of Climatic.Climatic is commercializing L Max, a daily inhaled system that proactively supports lung function.Before Climatic, Eric served as COO of Seed Health and was part of the foundational team at Chewy. Earlier in his career, Eric held growth and operational leadership roles across consumer, wellness, and e-commerce businesses, including Amazon, BoxyCharm, Target, and Best Buy. In this interview, Eric discusses what it takes to build a consumer category that doesn't yet exist, how Climatic approached clinical validation and consumer education simultaneously, and how early user behavior helped identify the company's strongest initial customer cohorts.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Eric Kau, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:49) - Eric's path through Amazon, Chewy, Seed, and the consumer health experiences that led to Climatic (05:49) - Why Climatic is treating lung health like hydration, sleep, or nutrition (11:47) - How Climatic rapidly iterated on formulas, delivery systems, and prototypes to launch a product for a new category in under 2 years (14:56) - Climatic's approach to product design, which is built around gym bags, vanities, and existing wellness routines (19:59) - How early users shaped both Climatic's clinical strategy and its go-to-market focus on endurance athletes and biohackers (23:56) - Why Climatic spent more time teaching consumers about lung health than selling the product itself (34:07) - What investors needed to believe before funding a category that didn't yet exist (40:27) - How Climatic built a 15,000-person waitlist through Strava run clubs instead of paid ads

Motivated by the notion that healthcare providers are seeking compliance solutions across the revenue cycle, the producers of Monitor Mondays have invited the CEO of Panacea Healthcare Solutions to serve as the special guest during the next upcoming broadcast.Introducing Kevin Chmura. For more than 25 years, Mr. Chmura has been at the forefront of major healthcare vendors as they, in turn, have worked to help their clients achieve success in revenue cycle compliance.Broadcast segments will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Cate Brantley, legislative affairs analyst for Zelis, will report on current healthcare legislation.

In the latest episode of the The Metal Pack Pod, we sit down with Meghan Barrera (Leader of the Global Strategic Marketing Group for PPG Packaging Coatings) in a live episode at the recent Metpack 2026 trade show.The metal packaging industry is currently navigating significant market shifts and macroeconomic challenges. On the consumer front, there is notable global growth in the traditionally flat pet food packaging sector, alongside a rising demand for "harder-to-hold" beverages—such as functional drinks, ready-to-drink (RTD) cocktails, and mixed alcoholic beverages. At the same time, brand owners and can makers are facing a complex regulatory "tsunami" of rapidly changing global and state-level legislations.This episode explores these shifting dynamics and highlights how PPG's latest coating innovations are engineered to drive operational efficiency and sustainability in response to these market conditions.

today we examine the 2026 landscape of artificial intelligence, specifically comparing proprietary and open-source models regarding privacy, cost, and legal compliance. Organizations must choose between proprietary APIs, hosted open-source solutions, and self-hosting to balance performance with data sovereignty requirements like HIPAA or the EU AI Act. While proprietary models currently lead in complex reasoning, open-source weights offer significant long-term cost savings and transparency for high-volume users. However, true total cost of ownership includes hidden expenses such as specialized talent, hardware infrastructure, and continuous model maintenance. Legal frameworks like the EU AI Act introduce strict obligations for high-risk systems, making explainability and governance essential for enterprise deployment. Ultimately, the transition from experimental pilots to industrialized AI factories requires mastering token economics and navigating the evolving regulatory environment.

This week on This Week in AML, Elliot Berman and John Byrne unpack major developments shaping the financial crime landscape. They discuss FinCEN's guidance expanding Section 314(b) information-sharing to include fraud and what it means for financial institutions. The conversation also covers new CFPB guidance on lending and immigration-related risks, increased IRS scrutiny of nonprofits, and enforcement actions from the UK and New Zealand. Plus, they explore growing concerns about the future of U.S. anti-financial crime leadership, the challenges of beneficial ownership transparency, and ongoing investigations tied to high-profile cases.

One of the most common sources of confusion in medical device Quality Management Systems is knowing when to open a Nonconformity (NC) and when to initiate a Corrective and Preventive Action (CAPA).Some organizations turn every issue into a CAPA, while others rarely open one at all. Both extremes can create challenges during audits and may indicate an immature quality system.In this episode of the Medical Device Made Easy Podcast, we explain the fundamental differences between NCs and CAPAs and explore real-life situations to help quality professionals make better decisions.A Nonconformity simply indicates that a requirement has not been met. A CAPA, however, is a structured process designed to investigate and eliminate the root cause of significant, recurring, or systemic issues.Through multiple scenarios, we discuss:When an isolated event should remain a simple NC.How trends and recurring problems justify CAPAs.Why a single event can trigger a CAPA when patient safety is involved.Whether a CAPA always requires a Nonconformity first.Alternative sources of CAPAs, including complaints, audits, PMS activities, PSUR reviews, PMCF activities, and management reviews.How auditors evaluate the maturity of a CAPA system.The three questions every quality professional should ask before deciding between an NC and a CAPA.The objective is not to open more CAPAs, nor to avoid them. The objective is to open the right CAPAs, based on risk, recurrence, and impact.Understanding this distinction is essential for building a robust and effective quality management system that supports compliance, patient safety, and continuous improvement.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Frank Ready, Manager of External Communications, Legal and Regulatory for Wolters Kluwer, sits down with EDRM's Mary Mack and Holley Robinson. In this episode, Frank talks about his journey from legal tech journalism to corporate communications and his transition to Wolters Kluwer. He shares how Wolters Kluwer approaches AI with legal professionals' specific needs in mind, key findings from their 2026 Future Ready Lawyer Survey on AI adoption and ROI, and the legal expertise behind their solutions that he wishes more in the industry knew about. The episode concludes with a celebrity fun fact from Frank and an invitation to connect with him on LinkedIn.

A fortnight ago it emerged all 6 members had left and that the Ministry of Health was assessing potential candidates to reconstitute the board.

Bank regulation has shifted fast over the last 18 months, and Ian Maloney, Chief Policy Officer at the American Fintech Council, joins Keith Daly on Travillian Next to break down what it means for bank compliance and risk teams. They get into why the prudential regulators are more coordinated, how reputation risk left the exam handbooks in favor of material financial risk, and the first CAMELS rating rewrite since 1996. Ian also lays out where AI governance, model risk, and fair lending stand for banks, how AI is reshaping fraud detection, and what the 2026 midterms could mean for bank supervision. A clear status check for anyone working in banking, fintech, compliance, or risk.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

Semafor reported that Flutterwave aims to become Africa's go-to fintech. The plan centers on unifying card payments, bank transfers, mobile money, and payouts under one provider across multiple African markets. Competition includes Safaricom's M-Pesa, MTN Group's MoMo, Paystack, and Chipper Cash. Regulatory approvals and compliance across countries such as Nigeria, Kenya, South Africa, and Egypt will determine execution speed. Merchants will evaluate providers on reliability, settlement, fraud controls, dispute handling, and foreign exchange tools. Partnerships with banks, telcos, card networks, and major platforms will influence adoption by enterprises and marketplaces.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Recorded: June 10, 2026This week, Barry and Ernest review the current state of the stock markets including the mega IPO of SpaceX before discussing the strong performance of the Canadian banks. 0:00- Introduction 6:01- SpaceX's IPO14:20- Elevated return expectations 22:21- Diversified Canadian banks28:03- Prime lending focus33:00- Canadian bank valuations38:54- Regulatory landscape

Nearly every American hospital has at least one physician advisor.So, how does the physician advisor at your facility measure up? We reached out to longtime physician advisor Dr. Juliet Ugarte Hopkins to address this issue in her capacity as the special guest for the upcoming live edition of the popular Talk Ten Tuesday broadcast.According to Dr. Ugarte Hopkins, also the chief medical officer for Phoenix Medical Management, “physician advisors should be involved in far more (activities) than secondary status reviews and peer-to-peer calls.”To learn more, register now to secure your seat at the table during the next live edition of Talk Ten Tuesday, coming up at 10 a.m. EST on Tuesday, June 16.Other well-known subject-matter experts will also join the broadcast with more news to report, including the following:• Part II: Coding and AI Senior healthcare analyst Frank Cohen, continues with Part 2 in his three-part series on coding and artificial intelligence.• POV: Penny Jefferson, cohost of Talk Ten Tuesdays, will share her point of view (POV) during the broadcast.• The Coding Report: Deanna Peterson, who will substitute for Christine Geiger, will report on the latest coding news.

Regulatory systems are infamous for creating “traps” in seem to be impervious to reform. Regulators seek to “drain the swamp,” but, instead, find themselves up to their necks in alligators.Original article: https://mises.org/mises-wire/moloch-regulatory-state

Deb 00:00:01Imagine your body has a repair manual, instructions written in your cells that tell tissues how to heal, blood vessels, how to grow, and inflammation when to stop. But what if those instructions got lost somewhere along the way? Well, today I’m talking about peptides, tiny protein fragments that act like biological text messages. Two of them, BPC 157 and TB 500.They’re showing remarkable promise for gut repair, joint recovery, and tissue regeneration. But here’s what nobody’s telling you. Women respond differently to these healing signals, especially during hormonal transitions. And today, we’re uncovering the science behind these regenerative peptides, who actually needs them, and why your doctor might not know about them. Can you guys put our ad right in here and then I’ll go to the standard intro?Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, explore cutting edge regenerative medicine, and empower you with the tools to heal. I’m Dr. Deb, your medical detective. And today we’re diving into regenerative peptides BPC157 and TB 500. If you or someone you love is struggling with slow recovery from injury, chronic joint pain, gut inflammation that just won’t quit, or you just feel like your body doesn’t bounce back the way it used to, this episode is for you. Grab a cup of coffee or tea or whatever helps you unwind, settle in, and let’s start you on your journey to deeper healing. We’ll do another sponsor break here. Deb 00:01:52So let’s start with the question I hear constantly in my practice. Dr. Deb, I’m doing everything right. I’m eating clean, I’m exercising, I’m taking my supplements, but I’m still not healing. What am I missing? Well, that answer might surprise you. Sometimes it’s not about what you’re putting in your body. It’s about whether your cells are actually receiving the repair signals they need. That’s where peptides come in. Think of peptides as The body’s original communication system. These short chains of amino acids are like biological post-it notes carrying instructions from one cell to another. They tell your human system when to calm down, your blood vessels when to grow and your tissues when to repair. Now here’s where it gets interesting for women specifically. We know that estrogen plays a massive role in collagen production, vascular health, inflammatory response. When estrogen starts declining, whether that’s perimenopause, postpartum, or even from chronic stress, our natural repair mechanisms slow down dramatically. You might notice it as my joints are aching more, I’m a little more fluid filled, you know, they hurt when I bend them, my injuries take twice as long to heal.Gut issues that suddenly appear out of nowhere and no matter what you do, they don’t seem to repair. Skin has lost its elasticity or just this general sense that your body isn’t keeping up anymore. This is where BPC 157 and TB 500 entered the picture. So BPC 157, short for body protection compound 157, is a naturally occurring peptide sequence found in your gastric juices. And according to a 2024 systemic review published in emerging use of BPC 157 in orthopedic sports medicine, this peptide promotes something called angiogenesis. That’s the formation of new blood vessels and they deliver oxygen and nutrients to damaged tissues. Now TB 500 is a synthetic fragment of thymus and beta-4. Deb 00:04:17A protein your body makes naturally during wound healing and research published in therapeutic peptides in orthopedics in 2025 shows that it works like a cellular first responder rushing to injury sites and coordinating tissue repair through a process called actin regulation. But here’s what makes these peptides different from just taking another supplement. They don’t force your body to do anything.They simply remind yourselves how to heal the way they used to. And for women navigating hormonal changes, autoimmune flares, chronic inflammatory conditions, that distinction matters enormously. all right, let’s get into some of these mechanisms because understanding how something works helps you make informed decisions about whether or not it’s right for you. So,Let’s look at the science. Do these peptides actually work? And if so, how do they work? Let’s start with BPC 157. This works through multiple pathways simultaneously. First, it activates growth factor receptors that stimulate fibroblasts. Those are the cells responsible for making collagen and rebuilding connective tissue. And according to research published in Frontiers and Pharmacology in 2023, titled Regeneration or Risk, BPC 157 also modulates nitric oxide signaling, which enhances vascular repair and reduces oxidative stress at the cellular level. So this is really important because many of us are nitric oxide deficient, especially as we get older, especially since the pandemic, we’re seeing a lot of people being more deficient in nitric oxide and you’re taking nitric oxide, many of you, to help with this process. But if we’re having other issues that don’t allow that nitric oxide to get where it needs to go, that could render it completely useless. So in plain English, when we’re talking about how BPC 157 helps the blood vessels work better and protects your mitochondria, big word for your energy factories and your cells from that inflammatory damage. Deb 00:06:38Now there’s studies in musculoskeletal and gastroenterology models that show BPC157 decreases inflammatory cytokines like TNF-alpha and IL-6. And these are chemical messengers that keep inflammation turned on. So by dialing them down, BPC157 creates an environment where healing can actually happen. Now, where do we know about this?TNFL and IL-6, well, we know it from viruses, we know it from Lyme disease, we know it from mold toxicity. These cytokines are turned up, they’re creating a massive inflammatory response in the body, and you’re struggling to get these things down because of that or potentially other reasons. So here’s where it gets really interesting with women in perimenopause or menopause. When estrogen declines, collagen synthesis slows down. And that’s why we see increased joint pain, slower wound healing, and our changes in the skin’s elasticity during this transition. We see the little wrinkles, the fine lines, we see the subcutaneous fat going away a little bit more. This is partially why this is occurring. And so from research shown in the Journal of Orthopedic Research in 2023 by Leibowitz and colleagues, that they suggest that BPC157 affects on the endothelial layers. So the cells lining the blood vessels and these may mimic some of the estrogen’s protective vascular effects without actually affecting your hormone levels. This is really huge because we know that as women lose estrogen, they have a higher risk for vascular events, heart attack, stroke, things like that. And if people have already had a heart attack or a stroke, We typically recommend that they don’t use estrogen because that could potentiate the risk for another heart attack or a stroke. But that means that you don’t gain the benefits of estrogen either. So if we think about this, we could potentially use BPC 157 to give us some of the benefits that we lost from having estrogen and potentially not being able to use estrogen. And that would be huge for us. Deb 00:08:57And not to mention the reduction of inflammation and the joint pain and the wound healing and the energy and the gut feelings. I mean, there’s just so many benefits to BPC 157 that we could talk about them all day long. But we’ve got to move on. So let’s talk about TB 500. Now this peptide works very differently. Its primary job is promoting cell migration, essentially telling repair cells to go to this spot and what to do when they get there. So it sends a signal, puts a little post-it stamp there and says, Hey, when you get there, fix A, B, C, and D. And there was a study in 2024 in cell biology international that demonstrated that TB 500 increases epithelial closure and improves tendon elasticity in models of repetitive strain injury. So let’s think about that a little bit. What does that really mean?That means faster recovery from exercise induced muscle damage, better healing of overuse injuries like tennis elbow or plantar fasciitis, improved scar tissue remodeling after surgery or a C-section, enhanced recovery from chronic inflammatory conditions affecting soft tissues. And I’ve talked about this several times. I have used these compounds post-surgical personally.And I remember going back to see my surgeon at the two to three week mark for follow-up. And she was amazed at how well everything was healing. And when I asked her if she wanted to know what I was doing, her response was no, but keep doing whatever you’re doing because it’s working. And after three weeks of a major pelvic repair surgery that I had, four hours in surgery, lots of sutures, not comfortable. I was actually walking a mile and didn’t have pain and I was recovering really well and felt amazing. And that is just not typically heard of in surgical procedures like mine. It’s usually a minimum of a six to eight week recovery before you’re starting to do that again. And I give all of the credit to these two peptides. Deb 00:11:17In my clinical practice, I see this play out constantly. Women who train hard, whether that’s CrossFit, running, yoga, or just trying to keep up with active kids, often hit a wall where their recovery can’t keep up pace with their activity level. And TB 500 helps to bridge that gap by optimizing the body’s natural repair timeline. But here’s what I want to emphasize with you. These peptides aren’t magic bullets.They work best when we combine them with proper nutrition and anti-inflammatory diet, adequate sleep, stress management, and we address the underlying root cause like the gut dysfunction or those hormonal imbalances. And they work much better when the hormones are balanced versus when they’re not. They’re amplifiers of your body’s existing healing capacity, not replacements for foundational health practices.So let’s have some real talk here. Let’s talk about evidence and what you need to know about that. Let’s take a drink, sorry. Now let’s address the elephant in the room. Regulatory status and safety. Neither BPC 157 or TB 500 are FDA approved for human medical use. They fall into a category called research compounds. And that means they’re legal to possess and use but they’re not approved as pharmaceutical drugs. And hopefully they will be back on our list of things to use relatively soon with the changes that Bobby Kennedy has made to peptides recently. So why does this matter? Because quality becomes a concern. Quality control is absolutely critical. You need to know where these compounds are manufactured, their source, their testing. their clarity, everything about them. There was a 2025 review in therapeutic peptides in orthopedics that concluded both peptides demonstrate strong regenerative signaling with minimal systemic side effects in preclinical studies. But, and this is really important, most of the robust data we have comes from animal models and cell culture models, not large scale human clinical trials. Deb 00:13:41Now that doesn’t mean that they don’t work. It just means that we are still in the early stages of understanding optimal dosing, treatment duration, and long-term effects in humans. So why do we have all of this great peptide information and we don’t quite have the ability to use them yet, or it’s extremely restricted?That comes under the guise of the FDA. came through the past administration with Biden where he removed a bunch of these peptides from the market. Both BPC and TB 500 were on the list of safe peptides to use before Biden made his changes. And it looks like they may be coming back relatively quickly for us here. So what we do have is growing clinical feedback from practitioners like myself. Who use these peptides in practice under careful supervision and under pilot studies on musculoskeletal recovery published in our organizations that we work with. So all of our information is documented and it is done under an observational study. There are other studies published in orthopedic and biomedical research from 2025.that actually found VPC-157 reduced pain scores by 35 % and improved functional mobility within eight weeks. This is really phenomenal because many people over the age of 40 are reaching for the Tylenol bottle, the Advil bottle, the Aleve bottle, which does a number on your kidneys and your gut and your liver. And it is really problematic to be using these things on a regular basis.And if we can use a compound that’s safe, that preserves the kidneys, the liver and the gut, why don’t we do that is the question that I have. Now, we see a lot of the same information in our clinic that we see in these studies. And it is the following things that we see. Significant reduction in joint pain and stiffness. I have a person that was looking at doing a knee replacement and we did 10 weeks of these two compounds. Deb 00:16:00And her knee pain reduced so much that she decided she didn’t feel like she needed that knee replacement right away, which is good because she is only 60 years old. And the length of that knee replacement wouldn’t be as long as it would if she could wait five or 10 years. The doctor didn’t say she needed to do it right away. She wasn’t that critical, but it was the pain that was driving her to the replacement. And so if we could preserve that and give her a reduction in pain, all the better to do that. We get faster recovery from surgical procedures, improved gut symptoms, especially in cases of leaky gut or inflammatory bowel conditions, better skin quality and wound healing, enhanced overall sense of resilience and recovery capacity. But here’s what you absolutely must know before considering peptide therapy. First, source matters. Because these aren’t FDA regulated pharmaceuticals, quality varies widely and you need to work with a physician who sources from compounding pharmacies 503A or 503B that provide certificates of analysis, third party testing and proper sterility verification. Secondly, context matters. Peptides work best as part of a comprehensive functional medicine approach. So if you’re still eating inflammatory foods, drinking alcohol, not managing your stress or your sleep, you have unaddressed gut dysfunction, and these peptides alone won’t fix those problems. Thirdly, realistic expectations matter. These aren’t overnight miracle cures. Most patients see gradual improvements over four to 12 weeks. Some respond dramatically, others see modest benefits. Individual variation is real. And fourth, medical supervision matters. Dosing, injection technique,monitoring for side effects and knowing when peptides are or are not appropriate. All of this requires clinical expertise. Now let me bust a few myths here because I hear this constantly. Myth number one, peptides are just for bodybuilders and athletes. That is false. While athletes use them for performance recovery, the therapeutic applications for chronic pain, gut healing and age related tissue decline are profound. Deb 00:18:26For everyday people. Myth number two, peptides will mess with my hormones. False. BPC-157 and TB-500 don’t interact with your endocrine system the way hormones do. They work through growth factors and cell signaling pathways. They are very different. Myth number three, if they’re not FDA approved, they must be dangerous. Not accurate.Many effective therapies exist in regulatory gray zones. What matters is quality sourcing, proper medical oversight, and informed consent. So the bottom line here is that these peptides show real promise backed by mechanistic science and growing clinical expertise, but they require responsible use, quality products, and realistic expectations. Now let’s talk about practical integration.Who should consider peptides? Well, so who actually benefits from the peptides? Let’s start there. Let me walk you through the three main categories I see. Number one is gut restoration. If you’re dealing with chronic gut inflammation, whether that’s IBS, inflammatory bowel disease, leaky gut, persistent digestive issues that haven’t responded to dietary changes alone, BPC 157 can be transformative.I had a patient recently, I’ll call her Sarah. She’s been struggling with severe gut pain and food sensitivities for three years. She tried elimination diets, probiotics, gut healing supplements, everything. And within six weeks of adding BPC 157 to her protocol, alongside the targeted nutritional therapy, her pain dropped by 70 % and she could tolerate foods that she hadn’t tolerated in years. Why does this happen? because BPC 157 directly supports mucosal integrity, the protective lining of your intestinal tract, and it reduces inflammatory cytokines and promotes healing of damaged tissue. Number two, muscle and joint recovery. This is where I see TB 500 shine. Women who are active, whether you’re a runner, a yogi, a cross-bitter, or someone who just wants to keep moving without pain. Deb 00:20:48They often hit a point where recovery becomes a very limiting factor. And maybe you’re dealing with chronic tendonitis, a nagging shoulder injury, a bad back that just will not quit, or just general achiness. It all makes you feel older and keeps you from being active the way you want to. TB 500 combined with therapies like red light therapy, PEMF, or targeted physical therapy, can dramatically accelerate soft tissue healing. I’ve seen recovery timelines cut in half for patients dealing with overuse injuries. Number three, menopausal transition support. This is where the intersection of peptides in women’s health gets really exciting. During perimenopause and menopause, declining estrogen affects collagen production, vascular health, and joint integrity, along with inflammatory processes and responses.Many women notice they just don’t heal as quickly and their joints hurt much more. Besides noticing their skin changes and their injuries linger longer. Low dose peptide protocols, often combining BPC157 for vascular and gut support with TB500 for soft tissue repair, can complement bioidentical hormone therapy or stand alone for women who can’t or don’t want to use hormones.Now I’m not saying that peptides replace your hormone optimization, but they can be powerful adjuncts that support tissue resilience during a time when your body’s natural repair mechanisms are shifting. Now, who should not use peptides? If you have any active cancer or a history of certain cancers, peptides that promote cell growth and angiogenesis might not be appropriate. If you’re pregnant or breastfeeding, we don’t have safety data.If you have severe kidney or liver disease, clearance and metabolism could be affected. You want to work with a practitioner who really understands this and be under medical supervision for these kinds of conditions. This really matters. A qualified functional medicine practitioner can assess your individual situation, run appropriate labs and determine whether peptides fit into your overall healing strategy. Remember, peptides are tools. They’re not magic. Deb 00:23:11They work best when you’re also addressing nutrition, sleep, stress, movement, and underlying root causes. They amplify your body’s healing capacity. They don’t replace the fundamentals. This is really important to understand. So thank you for joining me today on Let’s Talk Wellness Now. If this episode resonated with you, share it with another woman who’s ready to reclaim her body’s natural healing capacity. Remember, Wellness isn’t just about feeling good. It’s about thriving in every area of your life. Your body was designed to heal. You’re not a small version of a male. You are a woman with different biochemistry. And sometimes it just needs the right signals and the right support to remember how. If you’re ready to explore personalized regenerative medicine or peptide therapy as part of a comprehensive functional medicine approach,You can visit us at serenityhealthcarecenter.com. You can also follow us on Instagram, and you can look at my book, Seen at Last, and join the Seen at Last free community on Facebook, where we will provide all of this information and more for you. Until next time, I’m Dr. Deb, reminding you to take care of your body, mind, and spirit. Be well, and I’ll see you in the next episode.The post Episode 269 – Peptide Therapy for Women: How BPC-157 & TB-500 Heal Gut, Joints & Inflammation first appeared on Let's Talk Wellness Now.

Regulatory systems are infamous for creating “traps” in seem to be impervious to reform. Regulators seek to “drain the swamp,” but, instead, find themselves up to their necks in alligators.Original article: https://mises.org/mises-wire/moloch-regulatory-state

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry continue their series on major Express Entry reforms expected in Canada. They break down the two-track timeline for Express Entry changes, what is expected to change quickly through ministerial instructions, what will take longer through regulatory amendments, and how applicants should assess their current strategy before the deeper reform episodes begin. Key Topics Discussed Two-track timeline for Express Entry reforms Ministerial instructions versus regulatory amendments What is staying stable in Express Entry for 2026 High-wage occupation factors and future CRS changes Key Takeaways Express Entry is evolving, not collapsing, and many core features remain stable for now. Ministerial instruction changes could happen quickly and may affect CRS scoring factors. Regulatory reforms, including a potential merger of FSW, CEC, and FST, are expected later. Applicants should assess whether their occupation, Canadian experience, education, spouse, French, PNP, or job offer strategy may be affected. Quotes from the Episode: Mark Holthe: “Change is here. It is right on the doorstep.” Alicia Backman-Beharry: “It's so helpful to understand which reforms are coming and when they're coming.” Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

In this special Bowel Sounds and Nutrition Pearls collaboration episode, hosts Dr. Jennifer Lee and dietitian Nikki Misner speak with dietitian Lisa Richardson on infant formula. Lisa Richardson is a pediatric clinical dietitian and nutrition educator who brings together experience in pediatric specialty care, public health nutrition, and continuing education. She currently practices at UNC Children's Primary and Specialty Care Clinic. Across her publications, presentations, and clinical resources, Lisa focuses on making nutrition science usable, turning complex evidence into practical guidance that supports families, children, and the care teams who serve them.  Nutrition Pearls is supported by an educational grant from Mead Johnson Nutrition.Resources: Larson-Nath, et al. Term infant formula macronutrient composition: An update for clinicians. JPGN. 2025;80(5):751-759. doi:10.1002/jpn3.70002Rodrigo ML, et al.. Infant formula ingredients: Updates for clinicians.. 2024;78(5):1005-1008. doi:10.1002/jpn3.12192Lewis, et al. Reference Values for Macronutrients in Human Milk: the Mothers, Infants and Lactation Quality (MILQ) Study. Adv Nutr. 2025;16 Suppl 1(Suppl 1):100501. doi:10.1016/j.advnut.2025.100501Taylor SN, Buck CO. Post-discharge nutrition to optimize preterm infant short- and long-term outcomes. Semin Fetal Neonatal Med. 2025;30(2):101637. doi:10.1016/j.siny.2025.101637Abrams SA, et al. Food and Drug Administration Expert Panel on Infant Formula "Operation Stork Speed" June 2025: Part 1, Nutrient Considerations. Adv Nutr. 2026;17(4):100583. doi:10.1016/j.advnut.2025.100583Abrams SA, et al. Food and Drug Administration Expert Panel onInfant Formula "Operation Stork Speed" June 2025: Part 2, Regulatory and SafetyConsiderations. Adv Nutr. 2026;17(4):100584. doi:10.1016/j.advnut.2025.100584Abrams SA, et al. Food and Drug Administration Expert Panel on Infant Formula "Operation Stork Speed" June 2025: Part 3, Marketing of Infant Formulas, Breastfeeding Support, Hypoallergenic Formulas, and Nutrition for Preterm Infants. Adv Nutr. 2026;17(4):100585. doi:10.1016/j.advnut.2025.100585Pediatric Blue Book - Create personalized formula recipes and plans, and calculate nutritional needs using the dietitian-led, volunteer-run platform CDC Infant Formula Preparation and Storage Website U.S. FDA Infant Formula Homepage- Information on Operation Stork Speed, Closer to Zero Initiative, as well as view the listing of all non-exempt and exempt infant formulas that are currently available on the U.S. market.Produced by: Corey IrwinNASPGHAN - Council for Pediatric Nutrition Professionalscpnp@naspghan.org

Maureen Testoni, the stalwart president and CEO of the renowned 340B Health Program, will join the long-running Monitor Mondays todiscuss Eli Lilly's escalating demands for hospitals to submit in-house claims data as a condition of receiving 340B drug discounts. Who will blink first?Register now to reserve your participation.Broadcast segments will also include these instantly recognizable features:·      Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. ·      The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. ·      Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.·      Legislative Update: Folana Houston, legislative affairs analyst for Zelis, will report on current healthcare legislation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution. Novartis has made headlines with its investigational drug, Delpacibart Braxlosiran, which successfully met primary endpoints in a Phase 1/2 trial for treating Facioscapulohumeral Muscular Dystrophy (FSHD). This RNA therapy utilizes an antibody-oligonucleotide conjugate to target the DUX4 gene, a significant cause of FSHD. The promising results not only mark a potential therapeutic breakthrough for this debilitating neuromuscular disease but also highlight Novartis' commitment to innovative treatments in rare diseases. In parallel, Enliven Therapeutics has reported positive outcomes from a Phase 1 trial of ELVN-001 for patients with Chronic Myeloid Leukemia (CML), who are heavily pretreated. This small molecule tyrosine kinase inhibitor shows improved efficacy, offering hope for those who have exhausted existing treatment options. As ELVN-001 progresses into later-stage trials, it may significantly enhance therapeutic options and outcomes for CML patients. Regulatory activities remain at the forefront, exemplified by Amgen's engagement with the Duke Clinical Research Institute to defend Tavneos amid an FDA push for market withdrawal. This illustrates the intricate complexity of regulatory processes and the importance of evidence-based advocacy in preserving access to critical therapies. In another regulatory development, Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for Boehringer Ingelheim's Hernexeos targeting HER2-mutant non-small cell lung cancer. The approval emphasizes the growing significance of liquid biopsy technologies in personalized oncology care, offering precise and less invasive diagnostic solutions. In business development news, strategic collaborations are gaining momentum. Simcere Pharmaceutical has partnered with Stanford Medicine to develop first-in-class therapies for Idiopathic Pulmonary Fibrosis. Meanwhile, Ildong Pharmaceutical and Welt are joining forces to create AI-driven digital therapeutics. These alliances reflect an increasing trend towards integrating cutting-edge technology and cross-disciplinary expertise to accelerate drug discovery and development. Funding dynamics within the sector are evolving, as seen with Neion Bio's successful Series A fundraising of $23 million aimed at enhancing its biologics manufacturing platform. Similarly, Human Continuum secured $5.13 million to advance its exosome-based regenerative medicine platform. These investments underscore a strong focus on innovative platform technologies promising to transform therapeutic modalities and manufacturing processes. Not all news is positive, however; Jazz Pharmaceuticals and PharmaMar faced setbacks as their Phase 3 trial for Zepzelca (Lurbinectedin) failed to meet its overall survival endpoint in metastatic small cell lung cancer. This highlights the inherent challenges in oncology drug development and underscores the need for continuous innovation. Regulatory hurdles persist as well, evidenced by Camurus receiving a second complete response letter from the FDA regarding Oclaiz (Octreotide) due to manufacturing concerns. The industry is also navigating cybersecurity challenges, as seen with Novo Nordisk's recent data breach incident. This breach underscores vulnerabilities within biopharma companies concerning intellectual property and patient data protection. It serves as a stark reminder of the necessity for robust cybersecurity measures to safeguard sensitive information critical to clinical trials and corporate integrity. Meanwhile, strategic planning remains essential as Astellas confronts a looming $6 billion patent cliff with Xtandi, its prostate cancer drug. The company's five-year strategy focuses on cost savings while sustaining innovation and competitiveness amidst impending revenue declines. The biotechnology sector continues to thrive amidst these challenges, evidenced by record levels of initial public offerings (IPOs). Despite broader economic uncertainties, investor confidence remains robust, highlighting biotech's potential for groundbreaking advancements and lucrative returns. Finally, artificial intelligence is making significant strides across health agencies, with a reported 148% increase at the FDA by 2025 alone. This surge in AI integration highlights its transformative potential in regulatory processes and healthcare delivery—offering opportunities to enhance efficiency and decision-making within the sector. In summary, today's developments encapsulate the vibrant pharmaceutical and biotech industries characterized by scientific innovation, regulatory intricacies, strategic collaborations, and financial maneuvers. These advancements offer new hope for patients while navigating complex landscapes that demand continuous innovation and compliance—a balance that defines success in this ever-evolving sector.Support the show

I keep being accused of using AI. I've even been accused, more than once, of being AI-generated. So I owe you something better than irritation: an actual explanation of where I stand.In this episode, I work through the real concerns: the scraping of artists' work, the environmental cost, algorithmic bias, the fear of job displacement, the worry about deskilling, and argue that every one of them is a problem of how, not of whether. They are arguments for regulation, not for personal abstention. I talk about my own practice (yes, AI images sometimes; yes, Grammarly; no, not the writing or the thinking), about teaching at university in the middle of all this, and about why, as an anthropologist, I think this debate is really a debate about authorship and authenticity wearing a technological costume.The question, in the end, was never if AI. It was always, only, how.CONNECT & SUPPORT

Jack Burnham examines the Pentagon's 1260H list, which identifies Chinese companies allegedly assisting the PRC's military-industrial base, signaling increased regulatory scrutiny for these entities. Burnham recommends streamlining government lists to prevent companies from exploiting gaps and advises retail investors of the national security risks these firms pose. (6)1919

TODAY ON THE ROBERT SCOTT BELL SHOW: LIVE from Reno Nevada, Jonathan Emord, Bill Gates Influence Scandal, Pesticide Cancer Ruling, Joel Salatin Farm Freedom, Democrats Prefer Leaving, Vaccine Study Blowback, OB/GYN CDC LOL, Brain Death Reflections, Grocery Additives, Sugary Beverage Liver Cancer, and MORE! https://robertscottbell.com/jonathan-emord-bill-gates-nih-influence-scandal-pesticides-cancer-ruling-joel-salatin-regulatory-freedom-55-percent-of-democrats-prefer-leaving-vaccine-study-blowback-vaccine-safety-concerns-ob/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Health Canada has issued an interim Letter of No Objection that opens the door for broader use of spray drones in Canadian agriculture, a move industry leaders say will help growers protect crops in fields that are inaccessible to conventional equipment. The letter follows Health Canada's February proposal to allow drones to apply any crop... Read More

Randy Fearnow speaks with Jaya White, Partner, Quarles & Brady LLP, about the regulatory landscape surrounding the growing home infusion industry. They discuss issues related to the Medicare HIT benefit; home infusion-specific state licensure requirements; ambulatory infusion suites, IV hydration clinics, and med spas; Indiana's recent requirement that their Medicaid home care providers must also be certified for Medicare; and the regulatory definition of “homebound.” Jaya co-wrote an article for Health Law Connections about this topic. From AHLA's Post-Acute and Long Term Services Practice Group.Watch this episode: https://www.youtube.com/watch?v=9rd5xivY2YkRead Jaya's Health Law Connections article: https://www.americanhealthlaw.org/content-library/connections-magazine/article/488ffc74-684d-4c97-882c-eae034db75fa/Navigating-Regulatory-Pitfalls-at-the-Nexus-BetweeLearn more about AHLA's Post-Acute and Long Term Services Practice Group: https://www.americanhealthlaw.org/practice-groups/practice-groups/post-acute-and-long-term-servicesEssential Legal Updates, Now in AudioAHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.Stay At the Forefront of Health Legal EducationLearn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/. 

Scott Ensign, Chief Strategy Officer at Butler/Till, joins Ari Paparo to discuss the advantages of being a 100% employee-owned agency, the rise of agentic AI in media buying, AdCP adoption, and the future of pharmaceutical advertising. Learn how Butler/Till is leveraging AI-powered workflows, healthcare expertise, mobile gaming inventory, and programmatic innovation to drive growth in a rapidly evolving media landscape. Takeaways Butler/Till operates as a 100% employee-owned ESOP, giving employees ownership stakes and allowing the agency to remain independent and agile. The agency is a women-owned and women-led business, with roughly two-thirds of employees being women. Thanks to its status as an independent agency, Butler/Till can operate with agility, making faster decisions and investing strategically without outside shareholder pressure. Butler/Till takes a product-focused approach, building technology and solutions around client needs rather than creating products solely for commercialization. Pharmaceutical advertising is shifting away from broad-reach TV campaigns toward addressable, data-driven digital media channels. Even if pharmaceutical advertising regulations change, opportunities will remain through disease-state education and targeted healthcare professional outreach. Mobile gaming remains an undervalued advertising channel, particularly for reaching healthcare professionals during everyday moments. Butler/Till participated in one of the industry's earliest agentic AI-powered media transactions using AdCP technology. Agentic AI can automate traditionally manual workflows such as RFPs, publisher negotiations, and media planning. The agency views AI primarily as a tool for accelerating work and solving talent shortages rather than replacing employees. Chapters00:00 Introduction to Scott Ensign and Butler/Till00:41 What makes Butler/Till unique as an employee-owned agency01:24 The history behind Butler/Till's ESOP structure02:25 Independent agencies vs. holding companies03:47 Product development and technology investments at Butler/Till04:33 Why Butler/Till hired a Chief Product Officer05:08 How clients approach AI and workflow innovation06:33 The changing landscape of pharmaceutical advertising08:31 Regulatory concerns and the future of pharma marketing10:44 Reaching healthcare professionals in the digital age12:15 Why mobile gaming is an overlooked advertising opportunity14:19 Butler/Till's early agentic AI and AdCP media transaction16:25 How buyer and seller AI agents could negotiate media deals19:28 Why pharma is a strong fit for agentic media buying21:24 Expanding AdCP into audio and offline media channels23:01 AI, efficiency, and the future of agency work23:57 Butler/Till's growth, hiring plans, and closing thoughts Guests: Ari Paparo, Scott Ensign Learn more about your ad choices. Visit megaphone.fm/adchoices

This was a fun discussion about the serious issue of gasoline, diesel, and fertilizer price increases for farmers, ranchers, and consumers in California. Make no mistake, the actions taken by the Newsom administration have driven consumer prices to some of the highest in the United States. Gavin has taken California from almost energy independent to total dependence on imports.We have Mike Ariza, a downstream expert, who has been on the podcast several times. A great resource for boots-on-the-ground information on the California downstream market. Connect with Mike on his X account. @MikeAriza4531Also, we had Joseph Huitt, who is with the Bordin-Huitt California Almond Ranch. Check out their family products for honey and specialty almonds at https://bhalmondranch.com/1. California's Energy Crisis & Fuel DependencyMike Ariza, an energy expert, explains that California has become dangerously dependent on fuel imports (40% dependent). Two major refineries were converted to renewable diesel in 2023, taking 350,000 barrels of crude oil processing offline. This resulted in no gasoline or jet fuel production from those facilities. The Iranian conflict further disrupted supply chains, cutting off jet fuel, diesel, and gasoline shipments from Asian refineries. President Trump's waiver of the Jones Act allowed fuel from Gulf Coast refineries to reach California, preventing potential $10+ gasoline prices and shortages.2. Agricultural Challenges & Rising CostsJoseph from Borden Hewitt Ranch discusses the severe economic pressures on family farms:Red Diesel prices skyrocketed from $3.17/gallon in February to $4.79-$6.60/gallon by MarchFertilizer costs doubled from $300-$500/acre to $400-$700/acre due to Strait of Hormones closureAlmond prices have remained below the $2/pound break-even point for five yearsPayment delays: Farmers receive paychecks every 3-4 months, not weekly, creating cash flow challenges3. Water Rights & Agricultural RestrictionsJoseph describes severe water restrictions in California's San Joaquin Valley, where farmers are prohibited from irrigating during peak heat seasons (June-July) despite canals being full. Banks only finance half the land value due to water limitations, effectively halving farm viability.4. Regulatory Overreach & Equipment RestrictionsEPA regulations prevent farmers from repairing their own equipment without manufacturer accessA diesel mechanic was jailed for helping farmers and truckers repair enginesSoftware restrictions: Farmers can't access tractor software updates, limiting their ability to fix equipment independentlyTuning restrictions: Rice farmers need extra horsepower to navigate clay fields but face penalties if caught modifying engines5. GMO Seeds & Agricultural ContractsDiscussion about restrictive seed contracts where farmers must purchase new seeds annually and cannot replant saved seeds from previous years, creating ongoing dependency on seed companies.6. State Taxes & Economic BurdenMultiple taxes burden California farmers:Cap and Invest (called "Theft and Invest")Road taxes37 cents for bullet train funding80 cents for other state initiatives These taxes are passed directly to consumers through higher food prices.7. Food Supply Chain VulnerabilityIf California loses refinery capacity, diesel shortages would collapse logistics, resulting in:Only 3-5 days of food supply in metropolitan areasPort of Los Angeles unable to operateFood distribution across the entire country disrupted (LA is the largest food importer during winter)8. Family Farm Viability & Future GenerationsJoseph, at 25 years old, represents the challenge facing young farmers. While passionate about farming, he's pursuing a master's degree in biological science (studying avian influenza) because farming alone cannot support a family. His mother advised all children to pursue other careers while farming as a side activity—a common reality for modern family farms.Overall Theme: The podcast highlights how interconnected energy, agriculture, and regulatory policy are in California, and how state policies are making it increasingly impossible for family farms to survive while threatening regional and national food security.Hat tip to the Great John Rich for being named the Special Envoy to Farmers for the USDA. We have reached out to him to see about getting him on the podcast.Check out the Energy News Beat SubStack https://theenergynewsbeat.substack.com/A shout-out to Steve Reese and the Reese Energy Consulting group for sponsoring the Podcast https://reeseenergyconsulting.com/.Data2 if you have any business systems, can you trust A? Well, they have the patent on validation. . https://data2.zoholandingpage.com/energyAnd we have WellDatabase rolling in as a new sponsor. https://welldatabase.com/

Artificial intelligence is transforming healthcare, but developing an AI medical device is only part of the challenge. Manufacturers must also navigate certification requirements and maintain safety and performance throughout the entire product lifecycle.In two podcast episodes featuring Sandy Wright and Osman El-Koubani, we explore the journey from certifying LLM-driven medical devices to managing them after CE marking.Certifying LLM-Driven Medical DevicesLarge Language Models such as ChatGPT, Gemini, and Claude introduce new regulatory challenges. Unlike traditional software, these systems raise questions around predictability, validation, traceability, supplier management, and model updates.Topics discussed include:What defines an LLM-driven medical deviceClinical evaluation strategiesDemonstrating clinical benefitUsing commercial AI modelsSupplier controls and external dependenciesSignificant changes and model updatesLife After CE MarkingObtaining CE certification is not the end of the journey.AI medical devices require continuous monitoring once they reach the market.Manufacturers must address:Performance drift in real-world settingsCollection and analysis of real-world dataAI retraining and change managementPredetermined Change Control Plans (PCCPs)Post-Market Surveillance (PMS)Continuous safety and performance evaluationAI Devices Require a Lifecycle ApproachAI systems are dynamic technologies. Success depends not only on achieving certification, but also on maintaining control over performance, updates, and clinical safety throughout the product lifecycle.As regulations continue to evolve, manufacturers must combine robust development practices with proactive post-market monitoring to ensure long-term compliance and patient safety.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkSandy LinkedIn: https://www.linkedin.com/in/wrightsandy/Osman Linkedin: https://www.linkedin.com/in/osman-kan/Scarlet Linkedin: https://www.linkedin.com/company/scarlet-comply/posts/?feedView=all&viewAsMember=trueSocial Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Robert Leshner is the Founder and CEO of Superstate, as well as the former CoFounder of Compound.Most people in DeFi are focused on the $2.5 trillion cryptonative market. Robert is focused on the $700 trillion that hasn't moved onchain yet. In this episode, he explains why tokenization is the long awaited evolution for crypto markets, how Superstate is building the bridge between institutional TradFi assets and DeFi, and why the benefits of tokenization will soon lead to a hockey stick moment in DeFi and RWAs.------

Animal identification and basic traceability has long been a reality for Canada's cattle and sheep sectors, and upcoming regulatory changes will bring the goat industry much closer to the same framework. While implementation timelines are still being determined, industry leaders say the changes are aimed at improving animal health response, disease management, and future market... Read More

How should Texas address rising property taxes, growing concerns about public safety, and the challenges facing the state's criminal justice system? On this episode of Texas Talks, host Brad Swail sits down with State Representative Mitch Little, who represents Texas House District 65 in southern Denton County, for a wide-ranging discussion on criminal justice policy, government regulation, property tax reform, and the priorities shaping the next legislative session. Little, an attorney and member of the Texas House Committee on Criminal Jurisprudence, shares insights from recent interim hearings and discusses how lawmakers are evaluating issues ranging from rural attorney shortages and elder fraud to prosecutorial accountability and public safety. The conversation covers: • Rural attorney shortages and the concept of “legal deserts” • Law school debt, workforce incentives, and market-based solutions • Elder fraud and cryptocurrency kiosk scams targeting seniors • Regulatory challenges surrounding cryptocurrency transactions • Public safety and criminal justice reform priorities • Rogue district attorneys and prosecutorial accountability • Governor Abbott's proposal for a statewide prosecutor • Judicial discretion, bail policy, and repeat offenders • Property tax reform and school finance • Government spending and affordability concerns • Priorities for the 90th Texas Legislature Little also explains why he believes many public policy debates should focus on underlying market realities rather than government subsidies, particularly when addressing workforce shortages in rural communities. The discussion explores broader concerns about law enforcement, prosecutorial discretion, judicial accountability, and the balance between local control and state oversight in Texas' criminal justice system. Looking ahead, Little identifies property tax relief as one of the most significant issues facing Texas families and outlines his perspective on how lawmakers can reduce the burden on homeowners while maintaining essential public services. 00:00 — Intro + Meet Rep. Mitch Little 01:50 — Representing Texas House District 65 03:00 — What interim hearings accomplish 06:00 — Rural attorney shortages and legal deserts 08:39 — Law school debt and workforce incentives 12:15 — Are rural legal shortages really a crisis? 14:01 — Comparing attorney and physician shortages 19:20 — Market solutions versus government subsidies 20:24 — Elder fraud and cryptocurrency scams 23:07 — Why crypto kiosks are being scrutinized 25:33 — Should Texas regulate or ban crypto kiosks? 29:13 — Rogue district attorneys and lawlessness concerns 32:42 — Governor Abbott's statewide prosecutor proposal 34:02 — Elections, appointments, and accountability 37:42 — Property taxes and legislative priorities 39:26 — How Texas could fund property tax relief 41:00 — Final thoughts and where to follow Mitch Little Watch Full-Length Interviews: https://www.youtube.com/@TexasTalks Follow us on social mediaX: @Texas_DispatchInstagram: thetexasdispatchLinkedIn: The Texas DispatchTikTok: texas_talks_podcast Find more at The Texas DispatchYour source for state news, policy, and investigative journalism.https://thetexasdispatch.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Stay informed on current events, visit www.NaturalNews.com  - PJM Grid Crisis and Data Center Impact (0:10) - PJM's Reserve Shortfall and Price Controls (3:26) - Impact of Data Centers on PJM Grid (6:04) - Preparation for Power Outages (12:44) - Battery Technology and Future Investments (27:26) - IPOs and Market Bubbles (30:56) - Introduction of First Green Electric Skid Steers (54:09) - Advantages of Electric Skid Steers (1:05:56) - Challenges and Future of Electric Equipment (1:12:49) - Remote Control and Job Efficiency (1:22:42) - Skepticism and Operator Experience (1:27:35) - Product Models and Market Positioning (1:28:39) - Pricing and Maintenance (1:30:33) - Future of Electric Heavy Equipment (1:34:40) - Safety and Operator Training (1:44:13) - Customer Experience and Dealer Network (1:49:04) - Regulatory and Market Dynamics (1:52:02) - Future of Battery Technology (1:52:43) - Decentralized Living and Off-Grid Solutions (1:53:58) - Anniversary and Guest Announcements (2:25:52) - UNA Consultations and Market Demand (2:31:45) - Legal Recognition and Benefits of UNAs (2:35:07) - Risk Management and Liability (2:37:58) - Technology and Innovation (2:40:48) - Show Production and Guest Invitations (2:52:22) - Supporting Providers and Product Recommendations (2:52:38) - Closing Remarks and Future Plans (2:52:56) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here:

This is the afternoon All Local update for Tuesday June 9th, 2026.

What does the FDA's latest update on cosmetics regulation mean for beauty brands, manufacturers, and marketers? In this episode, we unpack how the FDA is expanding its oversight of the cosmetics industry through implementation of the Modernization of Cosmetics Regulation Act (MoCRA), the most significant overhaul of federal cosmetics regulation in more than 80 years. From mandatory facility registration, product listing, adverse event reporting, and safety substantiation requirements to forthcoming rules on good manufacturing practices, fragrance allergens, PFAS scrutiny, and talc testing, the agency is gaining unprecedented visibility into the cosmetics marketplace. As FDA signals that compliance, transparency, and product safety will remain key priorities, companies should prepare for heightened regulatory, litigation, and reputational risks in an increasingly scrutinized industry. Hosted by Simone Roach. Based on a blog post by Donnelly L. McDowell, Cristina Ferretti, and Katrina Hatahet.

Nick Jackson is the CEO and co-founder of Artist Partners, and collaborates with Andrew Mote, the Principal and Founder of Mote Advisors on analysing and advising superannuation funds on meeting their fiduciary responsibilities when it comes to their marketing investment. The explore the complexities of marketing within the Australian superannuation industry, focusing on regulatory scrutiny, measurement challenges, and strategic insights for marketers aiming to demonstrate member benefits and business outcomes. For a sector that manages more than $4.13 trillion in funds, making it one of the world's largest pension systems, and spending $482 million a year on marketing and sponsorship, this is an essential conversation to eavesdrop on. Listen on Apple: https://podcasts.apple.com/au/podcast/managing-marketing/id1018735190   Listen on Spotify: https://open.spotify.com/show/75mJ4Gt6MWzFWvmd3A64XW?si=a3b63c66ab6e4934   Listen on Stitcher: https://www.stitcher.com/show/managing-marketing   Listen on Podbean: https://managingmarketing.podbean.com/    For more episodes of TrinityP3's Managing Marketing podcast, visit https://www.trinityp3.com/managing-marketing-podcasts/   Recorded on RiversideFM and edited, mixed and managed by JML Audio with thanks to Jared Lattouf.

There's a quiet battle taking place, with no field hospitals for the sick and wounded, and no bloodshed.But the stakes are high, and the losses are unforgiving.It's the battle of algorithms.Employed by both payers and providers, the ultimate prize: money, in the form of reimbursement from submitted claims for medical care. Payers deny and recoup. Providers bill as margins shrink.During the next live edition of the ever-popular Talk Ten Tuesdays broadcast, senior healthcare analyst Frank Cohen, himself a veteran of algorithmic warfare, will escort you behind the front lines and into war rooms, so that you will have a better understanding of what is contributing to rising medical costs. Cohen's three-part article series on ICD10monitor.com begins this coming Tuesday.Other well-known subject-matter experts will also join the broadcast with more news to report, including the following:• POV: Penny Jefferson, cohost of Talk Ten Tuesday, will share her point of view (POV) during the broadcast.• CDI Report: Cheryl Ericson will provide an update on all things clinical documentation integrity (CDI).• The Coding Report: Christine Geiger will report on the latest coding news.

Regulatory volatility, scientific‑grade context requirements, and entrenched legacy processes are creating a level of operational complexity in pharma that makes even high‑value AI initiatives difficult to move from concept to production. In this episode, Art Shectman, CEO at Elephant Ventures, examines with host Marilie Fouché how leaders can cut through that complexity by isolating a single, clearly defined workflow slice and rebuilding it for near‑term, dependable deployment rather than long‑range architectural perfection. The discussion highlights how removing outdated process assumptions, selecting an atomic workflow with organizational alignment, and aiming for a contained operational win enable pharma teams to build momentum and scale AI responsibly in highly regulated environments. Learn how consultants are winning business with evidence-based AI ROI and building long-term capabilities instead of chasing short-term gains. Download our free PDF report, "3 Keys to Thriving in the Coming Era of Automation," at emerj.com/cok1

In this episode of Medsider Radio, we sat down with Kara Egan, founder and CEO of Teal Health.Teal Health is the company behind the first FDA-authorized at-home cervical cancer screening wand.Before founding Teal, Kara worked in healthcare and software investing at .406 Ventures and Emergence Capital, and held product and marketing roles at Zendesk and Stitch Labs.  In this interview, Kara discusses building support and follow-up into at-home screening, how Teal expanded its comparative clinical study to support broader market adoption, and how healthcare incentives, reimbursement, and institutional trust shape new care models.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Kara Egan, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:49) - Kara's background in health technology investing and software that shaped Teal's consumer-first approach (05:14) - How Teal turned the traditional Pap smear into the first FDA-authorized at-home screening product (07:30) - Turning at-home testing, telehealth, and clinician follow-up into a single care experience (13:48) - Raising Teal's first $1M with mockups and consumer-grade design (22:17) - Teal's comparative study that matched physician-collected screening with 96% sensitivity (23:40) - How asking women what they actually wanted changed Teal's view of the market opportunity (32:05) - “Take off the healthcare hat” — Kara's framework for fundraising, incentives, and commercialization (41:48) - What investors actually care about beyond the company's mission

At the heart of a recent lawsuit filed by a physician is whether the medical profession's understanding and practice of racial concordance is legally defensible.“Find-A-Black-Doctor” has served as a platform for Black, Indigenous, and Persons of Color (BIPOC) to locate providers who can offer them the best holistic treatment.However, some see this as discrimination against white-majority physicians, curtailing their access to potential patients.During my next live edition of Monitor Monday, Dr. Drew Updike, ] review the evidence behind concordance – as it pertains to women's health, BIPOC patients, and others – to provide you your team with an appreciation of its relevance in modern medicine.Broadcast segments will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Matthew Albright, chief legislative affairs analyst for Zelis, will report on current healthcare legislation.

Patrick McKenzie reads from his 2024 Bits About Money essay on ACATS, the Automated Customer Account Transfer Service that governs how Americans move investment accounts between brokerages, then updates it with regulatory developments (and industry infighting) from early 2026. The essay covers why a system underpinning trillions of dollars in assets was deliberately designed to skip verifying whether transfers are actually authorized, what the three-business-day shot clock means in practice, and how a bad actor armed with a stolen identity and a mobile app can drain someone's retirement account before they notice it's gone. (Good news, though: they'll almost certainly get it back. Bad news: quite stressful, and it often isn't obvious when staring at the zero that this is a recoverable condition.)–Full transcript available here: https://www.complexsystemspodcast.com/acats/ –Presenting Sponsors: Mercury & Granola If you have more interesting hobbies than managing your money, Mercury Personal is built for you. It allows you to automate movement between accounts—allocating paychecks and tax prep the moment they hit—with a sensible permissions model for partners or accountants. It works the way tech people expect banking to work. Go to mercury.com/personal to experience banking built by the same folks Patrick trusts for his business.If meetings consistently leave you with hazy action items and lost context, Granola handles the transcription so you can actually participate and gives you searchable notes afterward. Try it free at granola.ai/complexsystems with code COMPLEXSYSTEMS–Links:Guys what is wrong with ACATS: https://www.bitsaboutmoney.com/archive/how-acats-transfers-work/ –Timestamps:(00:00) Intro(01:49) A brief digression into self-regulatory organizations(03:04) FINRA regulates asset transfers between brokerages(04:54) How does one transfer securities account assets?(06:52) What does an ACATS request actually entail?(09:44) Brokerages frequently do not verify incoming ACATS requests(15:28) Recent developments in ACATS fraud(19:13) Should I be terrified, Patrick?(20:07) Sponsors: Mercury | Granola(23:17) Should I be terrified, Patrick? (cont'd)(24:46) Another fun wonky control(28:29) A final ACATS story(29:58) Regulatory updates: FINRA 26-02(32:34) Comment letters from the industry(43:20) Outro

(6) Michael Toth explains how Texas created specialized business courts and maintained a light regulatory touch to attract major corporations. The state is successfully challenging Delaware's dominance as the primary legal domicile for prominent American companies.

Join The Real Science of Sport Supporters club for ad-free listening and our exclusive weekly Applied Science show! A monthly donation is all takes!This week's Spotlight opens in Paris, where Roland Garros has delivered one of the most chaotic and compelling Grand Slams in recent memory, and ends on a Las Vegas track with a promise of $10 million unlikely to be fulfilled. Along the way, we explore retirements and comebacks, bike weight scandals, regulatory issues and a surprising way to boost your red blood cells.In today's Show:For the first time in the Open era, not a single former Grand Slam champion reached the men's round of 16. Ross and Gareth try to make sense of a tournament turned on its head by epically long five-set matches, multiple two-set-up defeats, and the emergence of potential new stars to challenge the duopoly atop men's tennisSinner is gone, Djokovic is gone, and the heat played a starring role. We revisit our applied show on heat adaptation to explain exactly why Sinner's implosion was both predictable physiologically, but surprising in its speed and persistenceSerena Williams has accepted a wildcard to play doubles at Queen's at 44. We explore the motivations for her return, and discuss why elite athletes retire in the first place? A thread on Discourse sparked by James gets us exploring the psychology and physiology of retirement, and why the grind we don't see is often the causeIn cycling, Lorena Wiebes was disqualified from the women's Giro after her bike allegedly weighed in 20 grams under the UCI's 6.8kg minimum. Was the punishment proportionate? Is the UCI's measurement process up to the required standard? Are SD Worx guilty of playing it too close to the limit? We discuss.A Belgian court has ruled against the UCI's attempt to impose gear ratio limits on the sport, finding the regulation neither necessary nor proportionate. We explore the implications well beyond cycling, and ponder how the UCI's failure to present a clear justification for the regulation was ultimately its undoingTilting your bed by six degrees could raise your EPO levels by 13% and increase hemoglobin mass by nearly 5%. Ross unpacks a genuinely fascinating new study, explaining why the mechanism is the same as altitude and heat training, whether the effect will be additive in athletes, and whether elite athletes are already quietly propping up their headboardsA carbohydrate question from supporter Tony ahead of his national canoe championships: does glycogen depletion in one muscle group affect availability elsewhere? Ross explains the elegant logic of local storage and use, the lactate shuttle, and why liver is the unsung hero of endurance fuellingAnd Finally, the Enhanced Games have announced a $10 million bonus for anyone who breaks Usain Bolt's 100m world record at their 2027 event. We discuss whether that will be enough to entice the truly fast man to race, doped or clean, and what it might mean for athlete's participation in the Olympics following an Enhanced Games Hosted on Acast. See acast.com/privacy for more information.

EPISODE DESCRIPTION Something bigger than taxes is driving America's corporate headquarters out of blue states—and executives are finally saying it out loud. In this episode, we break down the accelerating migration of major companies like Exxon and Silicon Valley giants into red states, not for payroll or tax relief, but for something far more fundamental: the legal system itself. From claims of “hostile courts” and unpredictable verdict environments to high-profile cases shaping corporate risk calculations, this conversation explores whether America is splitting into competing legal realities—and what that means for business, politics, and the future of investment in the United States. OPENING HOOK Finally, somebody said the quiet part out loud. For years, we were told corporations were fleeing blue states because of taxes, unions, or cheaper labor. But now executives are saying something different entirely: It's the courts. Not the tax code. Not the workforce. The legal system itself. SEGMENT 1: THE GREAT CORPORATE RELOCATION Big corporations are moving headquarters out of states they've been in for decades. California, New York, New Jersey—places that once anchored American business power—are losing companies at a steady pace. And according to executives, it's not about simple economics anymore. It's about legal predictability. Companies are increasingly choosing jurisdictions where courts are seen as more stable, more consistent, and less politically driven. Florida and Texas keep coming up—not just for taxes, but for legal structure and federal court alignment. SEGMENT 2: THE EXXON SIGNAL The clearest admission yet comes from ExxonMobil. When the company moved its legal headquarters from New Jersey to Texas, leadership didn't center taxes as the deciding factor. Instead, they pointed to something more sensitive: “Regulatory environment” and “hostile courts.” Executives emphasized the importance of operating in a state where legislators, judges, and juries “understand the business” and where legal exposure feels more predictable. Even more significant, the company aligned itself with a federal court jurisdiction outside Houston—highlighting how granular legal geography has become in corporate strategy. SEGMENT 3: THE ZUCKERBERG EFFECT Tech is following a similar pattern. High-profile legal battles involving major platforms have raised concerns about jury-driven damages, regulatory pressure, and politically charged litigation environments. Meta's legal challenges in certain jurisdictions, particularly in California, have intensified debates about whether social media companies are being shaped through courts rather than legislatures. The result: increasing interest in relocating operational or legal structures to states seen as more protective. SEGMENT 4: JUDGE SHOPPING AND LEGAL STRATEGY Behind the scenes, corporate legal teams are adapting. One growing practice is “judge shopping”—strategically filing cases in jurisdictions believed to offer more predictable outcomes. This isn't new, but it's becoming more central to corporate survival strategy as legal variability increases between states and federal districts. The concern from executives is not just losing cases—but facing inconsistent legal interpretations depending on geography. SEGMENT 5: THE BROADER DIVIDE What emerges is a fractured map of the United States: Some states are seen as business-friendly legal environments Others are viewed as high-risk litigation zones Federal court districts are now part of corporate relocation strategy In this framework, companies aren't just choosing where to operate. They're choosing which legal universe they want to live in. CLOSING TAKE Whether this trend represents a correction, a warning sign, or a permanent restructuring of American legal geography, one thing is clear: Corporate America is no longer just following the money. It's following the courts. And that changes everything. ...

Part 2 of our new format with three frontier founders: Guillermo Rauch (Vercel), Blake Scholl (Boom Supersonic), and Max Hodak (Science).  00:00 Previously… 00:34 The Regulatory Red Queen Race 05:13 Why There's No Innovation in Health Care 09:30 We Need a True 50-State Experiment 13:12 China's FDA Is Beating Ours 16:18 Healthcare Is a Communist Society Inside Capitalism 18:38 Sid's Story: N-of-1 Medicine Transcript: nav.al/regulatory

What if one of the most toxic products in your home isn't your cleaning spray, your cookware, or your water bottle… but the lip gloss sitting in your purse right now? In this eye-opening and deeply alarming conversation, Darin Olien sits down with clean beauty innovator, attorney, and consumer advocate Laura D'Alamo to expose what may be one of the biggest blind spots in modern health and beauty. After surviving triple-negative breast cancer and a near-fatal battle with COVID, Laura embarked on a two-year investigation into the cosmetic industry that uncovered a startling regulatory gap surrounding lip products, microplastics, toxic ingredients, and consumer safety. Together, they explore how lip products are regulated as external-use cosmetics despite being chronically ingested, why 80–90% of lip products may contain microplastics, how outdated regulations fail to reflect modern usage patterns, and why ingredients banned in food can still legally appear in products applied directly to the lips. They also discuss the launch of the Lip Service Alliance, the future of food-grade lip care, and how consumers can drive industry-wide change through awareness and purchasing decisions.     What You'll Learn Why lip products may represent a major overlooked toxic exposure pathway How cosmetics regulations differ from food and pharmaceutical regulations Why lip products are treated as external-use products despite being ingested The hidden role of microplastics in lip glosses, lipsticks, and lip balms Why flavored lip products may increase chronic ingestion How lip tissue differs biologically from normal skin The shocking absorption rates associated with oral mucosal tissue Why titanium dioxide is banned in European food but still used in lip products How outdated usage assumptions fail to reflect modern beauty habits Why the fastest-growing lip product market is girls ages 9–17 The mission behind the Lip Service Alliance How consumers can influence change through their purchasing decisions     Chapters 00:00:04 – Welcome to SuperLife 00:00:33 – Sponsor: Manna Vitality and frequency-enhanced wellness 00:01:59 – Introducing Laura D'Alamo and today's hidden toxic threat 00:02:35 – Triple-negative breast cancer and Laura's life-changing diagnosis 00:02:42 – Surviving COVID in the ICU and a profound existential awakening 00:03:00 – The cosmetic regulatory blind spot that changed everything 00:03:49 – Lip products containing thousands of microplastics per application 00:04:14 – Titanium dioxide, food bans, and regulatory contradictions 00:04:50 – The creation of the Lip Service Alliance 00:05:20 – Building the first food-grade lip care alternative 00:05:38 – Laura's legal background and journey through clean beauty 00:07:10 – Creating one of the first modern clean deodorant brands 00:08:23 – Innovation, consumer behavior, and predicting market shifts 00:09:29 – Consulting global beauty brands and seeing industry patterns 00:10:06 – Cancer diagnosis, purpose, and personal transformation 00:11:34 – Chemotherapy, ICU survival, and reevaluating life's mission 00:13:15 – The moment everything clicked into focus 00:13:59 – Returning to law and studying cosmetic regulations 00:14:25 – Why cosmetic regulations rarely keep pace with innovation 00:15:00 – Outdated assumptions still shaping modern beauty products 00:16:02 – Regulations built around usage patterns from decades ago 00:16:49 – Why this is a global issue—not just a U.S. problem 00:17:13 – Discovering the biggest blind spot in beauty history 00:18:15 – The late-night realization that launched two years of research 00:19:16 – Lip products classified as external-use cosmetics 00:21:02 – Why lip products are inevitably ingested 00:21:37 – Food-flavored lip products and TikTok taste-test culture 00:22:58 – Regulatory frameworks largely ignoring ingestion 00:23:53 – The EU's outdated lipstick usage assumptions 00:24:49 – The lead-in-lipstick controversy revisited 00:25:16 – Modern beauty consumers layering multiple lip products 00:26:16 – Heavy metals, PFAS, plastics, and cumulative exposure 00:27:12 – The $14 billion lip industry explained 00:27:34 – Why ages 9–17 are the fastest-growing demographic 00:29:00 – The shocking microplastic content of many lip products 00:29:44 – Why "clean beauty" often creates consumer confusion 00:30:15 – Hidden plastics even inside clean-positioned products 00:32:24 – Titanium dioxide and the food-versus-cosmetics paradox 00:33:20 – Genotoxicity concerns and cancer-related research 00:34:08 – Why regulators continue allowing it in lip products 00:35:04 – "You may love your lip products—but do they love you back?" 00:35:26 – The biological difference between lip tissue and skin 00:36:34 – Lip tissue as a highly absorbent biological portal 00:37:52 – Why standard skin testing may be misleading 00:38:17 – Testosterone, nicotine, and oral absorption comparisons 00:39:08 – Chronic exposure through ingestion and absorption 00:40:12 – Common sense versus regulatory assumptions 00:41:13 – Why parents react differently when children are involved 00:42:25 – The disconnect between protecting children and protecting ourselves 00:43:19 – Plastic detox research and fertility improvements 00:44:12 – Chronic inflammation and long-term health implications 00:45:07 – Quick wins consumers can implement immediately 00:45:47 – Why Laura spent two years building solutions before speaking publicly 00:46:30 – Launching the Lip Service Alliance 00:47:14 – Consumer awareness as the first step toward change 00:48:10 – Voting with your wallet and shifting industry behavior 00:48:52 – New scientific publications currently in peer review 00:49:50 – Creating new testing models for lip-specific safety 00:50:10 – Lip tissue absorbing up to hundreds of times faster than skin 00:51:00 – Why flavoring products encourages ingestion 00:52:14 – Petroleum-derived ingredients and bioaccumulation concerns 00:54:03 – Creating YAM: a 100% food-grade lip care company 00:55:29 – Building completely plastic-free packaging solutions 00:56:47 – Bioavailable ingredients and supporting natural lip biology 00:58:02 – The "dual pathway" problem: ingestion and absorption 00:59:00 – Hidden solvents and natural flavor loopholes 01:00:07 – Developing future food-grade lip products 01:01:04 – Why food-safe colorants are often illegal in cosmetics 01:02:28 – Regulatory barriers blocking safer innovation 01:03:37 – Simple policy changes that could transform the industry 01:04:23 – Darin reflects on Laura's relentless mission 01:05:32 – Why food-grade ingredients may work better biologically 01:06:21 – Regulatory modernization still missing lip-specific reforms 01:07:07 – The frustration of slow-moving bureaucracy 01:07:36 – Europe's timeline for microplastic warnings and bans 01:08:44 – Why consumers cannot afford to wait until 2035 01:09:29 – The aerosol-can analogy and how industries can change 01:09:49 – The role of consumer awareness and public pressure 01:10:38 – Why many brands don't even realize what's inside their formulas 01:11:18 – Inflammation, chronic exposure, and final warnings 01:11:57 – Closing thoughts and the future of lip safety advocacy     Thank You to Our Sponsors Shakeology: Get 15% off with code DARINO1BODI at Shakeology.com. Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order.     Join the SuperLife Community Get Darin's deeper wellness breakdowns — beyond social media restrictions: Weekly voice notes Ingredient deep dives Wellness challenges Energy + consciousness tools Community accountability Extended episodes Join for $7.49/month → https://patreon.com/darinolien     Find More from Laura DiGirolamo Website: https://yombeauty.com/  Instagram: @meetlauradigi Join: Lip Service Alliance     Find More from Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness      Key Takeaway "The biggest health threats are often the ones hiding in plain sight. Lip products are uniquely positioned at the intersection of ingestion, absorption, and chronic exposure, yet most regulatory systems still treat them as if they simply sit on the surface of the skin. Whether or not every concern raised in this conversation proves true over time, one thing is undeniable: consumers deserve better science, better transparency, and better products. And when enough people demand change, industries always find a way to evolve."